Angiogenesis is the formation and remodelling of new blood vessels and capillaries from growth of pre-existing blood vessels. It normally occurs during wound healing and embryonic development, but is also required for tumour growth and metastasis in cancer.

Items 1 to 50 of 319 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction
  1. BMS-690514

    Catalog No. A11263
    VEGFR/EGFR Inhibitor
    BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases. Learn More
  2. SU-5402

    Catalog No. A11558
    VVEGFR/FGFR/EGFR inhibitor‎
    SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively). Learn More
  3. PKC 412 (Midostaurin)

    Catalog No. A12650
    PKC inhibitor
    PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. Learn More
  4. Icotinib Hydrochloride

    Catalog No. A13718
    EGFR inhibitor
    Icotinib hydrochloride is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). Learn More
  5. AZD-9291 (Osimertinib)

    Catalog No. A13681
    EGFR inhibitor
    AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. Learn More
  6. Tyrphostin AG 183

    Catalog No. A13588
    EGFR inhibitor
    Tyrphostin AG 183 inhibits EGFR (epidermal growth factor receptor) tyrosine kinase (IC50 = 800 nM). Learn More
  7. CNX-2006

    Catalog No. A13755
    EGFR inhibitor
    CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer. Learn More
  8. Icotinib

    Catalog No. A13825
    EGFR inhibitor
    Icotinib is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). Learn More
  9. Afatinib dimaleate

    Catalog No. A14985
    EGFR inhibitor
    Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. Learn More
  10. Erlotinib mesylate

    Catalog No. A15081
    EGFR inhibitor
    Erlotinib mesylate is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM. Learn More
  11. Gefitinib hydrochloride

    Catalog No. A15093
    EGFR Inhibitor
    Gefitinib hydrochloride is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR. Learn More
  12. VEGFR/EGFR inhibitor
    Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM. Learn More
  13. WHI-P180

    Catalog No. A15509
    EGFR/Cdk2 inhibitor
    WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively. Learn More
  14. AZ5104

    Catalog No. A15516
    EGFR inhibitor
    AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1. Learn More
  15. AZD3759

    Catalog No. A15551
    EGFR inhibitor
    AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR). It binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Learn More
  16. ASP8273 (Naquotinib)

    Catalog No. A14408
    irreversible EGFR inhibitor
    ASP8273 is an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Learn More
  17. EGF816 (Nazartinib)

    Catalog No. A14416
    EGFR T790M inhibitor
    EGF816 is a novel covalent inhibitor of mutant-selective EGFR; overcomes T790M-mediated resistance in NSCLC. Learn More
  18. AG-18 (Tyrphostin 23)

    Catalog No. A15940
    EGFR Inhibitor
    AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 ,M in the human epidermoid carcinoma cell line A431. Learn More
  19. DM1-SMCC

    Catalog No. A15955
    potent EGFR inhibitor
    DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate. Learn More
  20. Antioxidant, antiangiogenic, antitumor agent
    (-)-Epigallocatechin gallate is a potent anti-oxidant polyphenol flavonoid isolated from green tea. Learn More
  21. Pelitinib (EKB-569)

    Catalog No. A10706
    EGFR inhibitor
    Pelitinib (EKB-569) is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. Learn More
  22. Neratinib (HKI-272)

    Catalog No. A10638
    HER2 inhibitor
    Neratinib (HKI-272) is a tyrosine kinase inhibitor. Learn More
  23. Canertinib (CI-1033)

    Catalog No. A10211
    HER2/ErbB2 inhibitor
    Canertinib (CI-1033) is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM). Learn More
  24. BIBW2992 (Afatinib)

    Catalog No. A10141
    EGFR inhibitor
    BIBW2992 (Afatinib) is tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Learn More
  25. AZD8931 (Sapitinib)

    Catalog No. A10116
    pan-EGFR/pan-erbB inhibitor
    AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling. Learn More
  26. WZ4002

    Catalog No. A10991
    EGFR Inhibitor
    WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib. Learn More
  27. Gefitinib (Iressa)

    Catalog No. A10422
    EGFR Inhibitor
    Gefitinib is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Learn More
  28. Erlotinib HCl

    Catalog No. A10362
    EGFR inhibitor
    Erlotinib hydrochloride is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). Learn More
  29. Lapatinib Ditosylate

    Catalog No. A10514
    HER2 inhibitor
    Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. Learn More
  30. EGFR Inhibitor
    AG-1478 (Tyrphostin AG-1478) is an inhibitor of EGFR kinase with an IC50 value of 3 nM. Learn More
  31. OSI-420

    Catalog No. A10678
    EGFR Inhibitor
    OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain . Learn More
  32. CUDC-101

    Catalog No. A10246
    HDAC inhibitor
    CUDC-101 is a novel compound which inhibits multiple targets, which is designed to inhibit HDAC, EGFR and Her2. Learn More
  33. WZ8040

    Catalog No. A10992
    EGFR Inhibitor
    WZ8040 is a novel EGFR inhibitors that suppress the growth of EGFR-T790M-containing cell lines and inhibit EGFR phosphorylation. Learn More
  34. WZ3146

    Catalog No. A10990
    EGFR Inhibitor
    WZ3146 is an inhibitor of EGFR receptor kinase mutants carrying a mutation in an active site gatekeeper residue (T790M) and is much less potent against wild-type EGFR kinase. Learn More
  35. PD153035 (HCl salt)

    Catalog No. A10702
    EGFR inhibitor
    PD153035 is an extremely potent and specific inhibitor of the tyrosine kinase activity of EGFR. Learn More
  36. CP-724714

    Catalog No. A10242
    HER2/ErbB2 inhibitor
    CP-724714 is an orally available, small molecule, potent HER-2 tyrosine kinase inhibitor that inhibits HER2 kinase (IC50 3.8 ng/ml) . Learn More
  37. BMS 599626 (AC480)

    Catalog No. A11209
    EGFR Inhibitor
    BMS 599626 is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50=22, 32 and 190 nM, respectively) with potential antineoplastic activity. Learn More
  38. Arry-380 analog

    Catalog No. A11027
    HER2 Inhibitor
    ARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. Learn More
  39. AV-412

    Catalog No. A11028
    EGFR inhibitor
    AV-412 is an EGFR/HER2 inhibitor that binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may result in the inhibition of tumor growth and angiogenesis. Learn More
  40. AG-490

    Catalog No. A10047
    EGFR inhibitor
    AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src. Learn More
  41. AEE788

    Catalog No. A10043
    EGFR inhibitor
    AEE788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor that inhibits phosphorylation of the tyrosine kinases of EGFR, HER2 and VEGF2. Learn More
  42. EGFR inhibitor
    Chrysophanic acid (Chrysophanol) blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway. Learn More
  43. EGFR inhibitor
    PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. Learn More
  44. XL647 (Tesevatinib)

    Catalog No. A11057
    GFR, HER2 and VEGFR inhibitor
    XL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4. Learn More
  45. AST-1306

    Catalog No. A11155
    EGFR Inhibitor
    AST-1306, a novel anilino-quinazoline compound, inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems. Learn More
  46. Daphnetin

    Catalog No. A10286
    EGFR, PKA,PKC inhibitor
    Daphnetin is a coumarin analog that acts as an inhibitor of several protein kinases. It inhibits EGFR kinase (IC50 = 7.67 µM), PKA (IC50 = 9.33 µM), and PKC (IC50 = 25 µM), in vitro. The inhibition of EGFR kinase by daphnetin was competitive to ATP and non-competitive to the peptide substrate. Also acts as a potent antioxidant and anti-malarial agent. Learn More
  47. Mubritinib (TAK 165)

    Catalog No. A10612
    HER2/ErbB2 inhibitor
    Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Learn More
  48. ARRY334543 (Varlitinib)

    Catalog No. A11158
    EGFR inhibitor
    ARRY334543 is a potent, orally active small molecule inhibitor of EGFR and ErbB-2. Learn More
  49. Genistin (Genistoside)

    Catalog No. A10426
    Genistin is an isoflavone found in a number of dietary plants like soy and kudzu. It was shown to stimulate estrogen-dependent breast cancer cell growth in vivo. Learn More
  50. TAK-285

    Catalog No. A11236
    HER2/EGFR inhibitor
    TAK-285 is an investigational HER2/EGFR inhibitor that penetrates the CNS in Rats with an Intact Blood Brain Barrier (BBB). TAK-285 has inhibitory activity against HER2 and EGFR kinases with IC50 values for HER2 and EGFR of 17 nmol/L (95% CI 12-24) and 23 nmol/L (95% CI 18-30), respectively.[1] Learn More

Items 1 to 50 of 319 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction